posted
ChromoCure Announces Mayo Clinic Research Confirms Its Technology and Chromosomal Basis of CancerFont size: A | A | A8:01 AM ET 1/5/10 | Market Wire ChromoCure, Inc. PINKSHEETS: KKUR is pleased to announce the basis for the Company's technology confirmed by recent Mayo Clinic researchers. Their findings, which appear in the current issue of the journal Cancer Cell, along with an independent commentary on the discovery, end a major controversy in the field of cancer research as to whether aneuploidy is a cause or a consequence of cancer and further proves the aneuploidy basis of cancer. This recent publication enhances the company's international activities to promote its cancer detection system and related technology through its ChromoCure Cancer Research & Diagnosis Centers program. The research further confirms the chromosomal theory of cancer and immediately establishes the company's technology in the forefront of both cancer detection and research.
ChromoCure's proprietary CS200 Chromosomal Scanner system and related technology is specifically designed to target the unique chromosomal characteristics demonstrated in the Mayo Clinic research. Detecting the unique chromosomal signature of cancer yields an effectively 100% accurate method of detecting all forms of cancer at all stages.
The company's systems detect the single characteristic found in 100% of all cancers at all stages, and never found in normal cells. The company therefore believes its technology detects cancer with an effective 100% specificity and effective 100% accuracy. The Company's technology also objectively measures, with high precision, the level of cancer present and its stage of progression.
About Mayo Clinic
Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of "the needs of the patient come first." More than 3,700 physicians, scientists and researchers, and 50,100 allied health staff work at Mayo Clinic, which has campuses in Rochester, Minn., Jacksonville, Fla. and Scottsdale/Phoenix, Ariz.; and community-based providers in more than 70 locations in southern Minnesota, western Wisconsin and northeast Iowa. These locations treat more than half a million people each year.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's proprietary ChromoCure CS200 Chromosomal Scanner system measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide.
The Company's technology and cancer expertise also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.
Safe-Harbor Statement
This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
Contact: ChromoCure, Inc. www.ChromoCure.com info@chromocure.com Tel 1.775.636.6548
posted
This one went to 0.0012 today and droped right back to where it started 0.0007. Thanks to profit takers or maybe total dilution.
Posts: 602 | From: Minneapolis | Registered: Jul 2009
| IP: Logged |
posted
ChromoCure, Inc. Announces Major Therapeutics Research ""ProjectBoveri: Find the Cure""
Feb 2, 2010 08:30:20 (ET)
RENO, NV, Feb 02, 2010 (MARKETWIRE via COMTEX) -- ChromoCure, Inc. (PINKSHEETS: KKUR) announced today the launch of a major new research initiative targeting Cancer Therapy and Cure. The Company has realigned its business strategy due to corroboration by recent Medical Research publications that both validated ChromoCure's chromosomal/aneuploidy theory of cancer and immediately established the company's proprietary ChromoSomal Scanner technology in the forefront of both cancer detection and research. The company will announce new partnerships, products, licensing, and laboratory activities based on this research-oriented alignment.
Research has conclusively, and irrefutably demonstrated aneuploidy as a more accurate predictor of cancer than cytological/histological analysis or genetic marker-based diagnostics that are the only other methods in existence today. ChromoCure's proprietary technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research.
The company's technology and research combined with unique insights provided by the chromosomal theory of cancer paves the way for non-invasive and non-toxic solutions to cancer therapeutics and disease eradication. ChromoCure's ChromoSomal Scanner Technologies, encompassing proprietary designs, processes, and algorithms, provides significant advantage in delivering important and significant results in both therapy and cure.
Support by these recent third party medical findings, the Company is calling for a stepped up collaborative approach through its "Project Boveri: Find the Cure" initiative; and is inviting industry, institutions, medical research centers and government to partner in this initiative. The company has already established a special section of its web site dedicated to this project and research outreach. The Company's recently announced diagnostic partnership program with pathologists and diagnostic labs will be incorporated into Project Boveri in order to broaden awareness of the company's technology.
The company will provide cancer detection and progression measurement services using its own equipment to research partners participating in the Project Boveri initiative. "Project Boveri" is named after Theodor Boveri who first described the chromosomal/aneuploidy theory of cancer diagnosis nearly a century ago.
The company will soon announce the details on various collaborative research centers participating in "Project Boveri: Find the Cure".
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems and technologies. The Company's proprietary ChromoCure CS200 Chromosomal Scanner system has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has been proven to have an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure.
Safe-Harbor Statement
This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
posted
ChromoCure Rebrands Corporate Image and Realigns Operations toReflect Its Pioneering Role in Cancer Detection, Therapy and Cure
Feb 22, 2010 08:30:41 (ET)
RENO, NV, Feb 22, 2010 (MARKETWIRE via COMTEX) -- ChromoCure, Inc. (PINKSHEETS: KKUR) announced today the official launch of its realigned business strategy and its corporate rebranding. The Company recently announced its accelerated Therapy and Cure initiatives through the launch of Project Boveri: Find the Cure; and the new branding properly reflects its pioneering role in cancer detection, therapy and cure; and its increased research programs and collaborations. Learn more about the company's new branding and initiatives at www.ChromoCure.com .
As recently announced the Company realigned its business strategy due to corroboration by recent Medical Research publications that both validated ChromoCure's chromosomal/aneuploidy theory of cancer and immediately established the company's proprietary ChromoSomal Scanner technology in the forefront of both cancer detection and research.
Research has conclusively, and irrefutably demonstrated aneuploidy as a more accurate predictor of cancer than cytological/histological analysis or genetic marker-based diagnostics that are the only other methods in existence today. ChromoCure's proprietary technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research.
The company's technology and research combined with unique insights provided by the chromosomal theory of cancer paves the way for non-invasive and non-toxic solutions to cancer therapeutics and disease eradication. ChromoCure's ChromoSomal Scanner Technologies, encompassing proprietary designs, processes, and algorithms, provides significant advantage in delivering important and significant results in diagnosis therapy and cure.
Supported by recent third party medical findings, the Company launched its collaborative research approach with its "Project Boveri: Find the Cure" initiative; and is inviting industry, institutions, medical research centers and government to partner in this initiative. The company has already established a special section of its web site dedicated to this project and research outreach. The Company's recently announced diagnostic partnership program with pathologists and diagnostic labs will be incorporated into Project Boveri in order to broaden awareness of the company's technology.
The company will soon announce various collaborative research agreements as well as progress reports on new partnerships, products, licensing, and laboratory activities based on its research-oriented alignment.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems and technologies. The Company's proprietary ChromoCure CS200 Chromosomal Scanner system has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has been proven to have an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure.
Safe-Harbor Statement
This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
posted
I guess the are releasing news compared to not doing anything at all.
Posts: 94 | From: Minneapolis, Mn. 55458 | Registered: Feb 2000
| IP: Logged |
posted
ChromoCure Completes Realignment of Management as First Step inTransition to Cancer Therapy and Cure Research & Development
Mar 1, 2010 13:51:14 (ET)
RENO, NV, Mar 01, 2010 (MARKETWIRE via COMTEX) -- ChromoCure, Inc. (PINKSHEETS: KKUR) announced today the completion of the first major step in its transition to a focused Cancer Therapy and Cure Research & Development organization. The Company recently announced its accelerated Therapy and Cure initiatives through the launch of Project Boveri: Find the Cure; properly reflecting its pioneering role in cancer detection, therapy and cure; and its increased research programs and collaborations.
This major realignment of the Company's business strategy includes the departure of all prior management. The Company will soon announce its new management team with proven credentials to maintain ChromoCure's leadership and pioneering role in Cancer Therapy and Cure initiatives worldwide.
As recently announced the Company had realigned its business strategy due to corroboration by recent Medical Research publications that both validated ChromoCure's chromosomal/aneuploidy theory of cancer and immediately established the company's proprietary Chromosomal Scanner technology in the forefront of both cancer detection and research.
Research has conclusively, and irrefutably demonstrated aneuploidy as a more accurate predictor of cancer than cytological/histological analysis or genetic marker-based diagnostics that are the only other methods in existence today. ChromoCure's proprietary technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research.
The company's technology and research combined with unique insights provided by the chromosomal theory of cancer paves the way for non-invasive and non-toxic solutions to cancer therapeutics and disease eradication. ChromoCure's ChromoSomal Scanner Technologies, encompassing proprietary designs, processes, and algorithms, provides significant advantage in delivering important and significant results in diagnosis therapy and cure.
Support by these recent third party medical findings, the Company is calling for a stepped up collaborative approach through its "Project Boveri: Find the Cure" initiative; and is inviting industry, institutions, medical research centers and government to partner in this initiative. The company has already established a special section of its web site dedicated to this project and research outreach. The Company's recently announced diagnostic partnership program with pathologists and diagnostic labs will be incorporated into Project Boveri in order to broaden awareness of the company's technology.
The company will provide timely updates on new management as well as progress reports on new management appointments; as well as partnerships, products, licensing, and laboratory activities based on this research-oriented alignment.
About ChromoCure ChromoCure develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company's proprietary CS200 Chromosomal Scanner has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure. The Company also applies its technology and knowledge to cancer cure and therapeutics research.
Safe-Harbor Statement This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
